Open Access<p>A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease</p>
Author(s) -
Mike Taylor,
George W Ousler,
Gail Torkildsen,
Claire A. Walshe,
Matthew C. T. Fyfe,
Adele Rowley,
Steve Webber,
John D. Sheppard,
Ajay Duggal
Publication year - 2019
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s189039
Subject(s) - medicine , placebo , tolerability , artificial tears , adverse effect , population , randomized controlled trial , ophthalmology , surgery , pathology , alternative medicine , environmental health
To evaluate the safety and efficacy of topical TOP1630, a novel nonsystemic kinase inhibitor, in dry eye disease (DED).